National Pension Service Has $1.33 Billion Stock Position in Johnson & Johnson $JNJ

Key Points

• National Pension Service increased its Johnson & Johnson stake by 1.3% in the second quarter, bringing its holdings to 5.23 million shares valued at approximately $1.33 billion. Institutional investors collectively own 69.55% of J&J.
• Johnson & Johnson reported quarterly revenue of $25.31 billion, up 6.6% year over year, and adjusted EPS of $2.90, beating estimates. The company reiterated fiscal 2026 EPS guidance of $11.60–$11.75 and pays a $1.34 quarterly dividend, yielding about 2%.
• Investor sentiment is supported by promising lung-cancer data and potential value creation from a reported DePuy Synthes sale, but risks include a failed mid-stage depression-drug trial, ongoing STELARA-related pressure and recent insider share sales.

National Pension Service grew its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 1.3% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,226,968 shares of the company's stock after purchasing an additional 67,484 shares during the period. Johnson & Johnson comprises approximately 0.9% of National Pension Service's investment portfolio, making the stock its 21st biggest holding. National Pension Service owned approximately 0.22% of Johnson & Johnson worth $1,327,493,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. Engineers Gate Manager LP boosted its position in Johnson & Johnson by 203.1% during the second quarter. Engineers Gate Manager LP now owns 3,449 shares of the company's stock valued at $876,000 after purchasing an additional 2,311 shares during the last quarter. Pinnacle Wealth Management Advisory Group LLC raised its stake in shares of Johnson & Johnson by 1.0% during the 2nd quarter. Pinnacle Wealth Management Advisory Group LLC now owns 81,540 shares of the company's stock worth $20,709,000 after purchasing an additional 830 shares in the last quarter. NorthRock Partners LLC boosted its holdings in shares of Johnson & Johnson by 4.7% in the 2nd quarter. NorthRock Partners LLC now owns 36,605 shares of the company's stock valued at $9,297,000 after buying an additional 1,652 shares during the last quarter. Integrated Wealth Concepts LLC boosted its holdings in shares of Johnson & Johnson by 20.9% in the 2nd quarter. Integrated Wealth Concepts LLC now owns 143,254 shares of the company's stock valued at $36,382,000 after buying an additional 24,787 shares during the last quarter. Finally, Community Bank N.A. grew its stake in shares of Johnson & Johnson by 1.5% in the second quarter. Community Bank N.A. now owns 47,062 shares of the company's stock valued at $11,952,000 after buying an additional 697 shares in the last quarter. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Price Performance

Shares of JNJ opened at $267.35 on Thursday. The company's 50-day moving average is $263.25 and its 200-day moving average is $246.40. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The firm has a market capitalization of $644.28 billion, a PE ratio of 30.98, a PEG ratio of 2.55 and a beta of 0.24. Johnson & Johnson has a fifty-two week low of $173.33 and a fifty-two week high of $281.07.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business had revenue of $25.31 billion during the quarter, compared to the consensus estimate of $25.06 billion. During the same quarter in the previous year, the firm posted $2.77 EPS. Johnson & Johnson's revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Equities analysts forecast that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th were issued a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date was Tuesday, August 25th. Johnson & Johnson's payout ratio is currently 62.11%.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Promising lung-cancer results strengthen J&J’s growth outlook. New Phase 2b and Phase 3 data showed that RYBREVANT-based combinations for EGFR-mutated non-small-cell lung cancer delivered improved tolerability, fewer treatment-related adverse events and longer reported overall survival. The results could support adoption of RYBREVANT and LAZCLUZE in first-line treatment. Johnson & Johnson Reports Stronger Survival Data in EGFR-Mutated Lung Cancer
• Positive Sentiment: Underlying business momentum remains resilient despite STELARA pressure. Management said sales increased 5.6% excluding the roughly 460-basis-point drag from STELARA, encouraging investors to focus on growth from the broader pharmaceutical and MedTech portfolios. The company previously reported quarterly revenue of $25.31 billion, up 6.6% year over year, and adjusted EPS above consensus. Should You Judge JNJ Stock Without STELARA?
• Positive Sentiment: Potential value creation from a DePuy Synthes sale is attracting investor interest. Apollo Global Management is reportedly considering acquiring J&J’s orthopedics business for close to $20 billion. A transaction could unlock value, sharpen J&J’s portfolio focus and provide capital for acquisitions or shareholder returns, although no deal has been announced. Apollo and J&J Face a High-Stakes Orthopedics Deal
• Neutral Sentiment: J&J remains viewed as a defensive, dividend-oriented healthcare holding. Its roughly 2% yield, recent outperformance and FY 2026 EPS guidance of $11.60–$11.75 support the investment case, but a valuation near 31 times earnings leaves less room for execution disappointments.
• Negative Sentiment: A partnered depression drug failed a key Phase 2 endpoint. Contineum Therapeutics said the MOONLIGHT-1 trial of JNJ-5120/PIPE-307 did not meet its primary efficacy goal in major depressive disorder. J&J is reviewing additional data, but the setback weakens the near-term pipeline contribution from the program. Johnson & Johnson-Partnered Contineum Depression Drug Fails Mid-Stage Trial
• Negative Sentiment: Reported insider activity shows executives have sold shares without any purchases during the past six months, a potentially cautionary sentiment signal, though such transactions may reflect diversification or scheduled sales rather than a fundamental view of JNJ.

Insider Transactions at Johnson & Johnson

In other news, EVP Timothy Schmid sold 33,597 shares of the company's stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the transaction, the executive vice president owned 25,447 shares of the company's stock, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Elizabeth Forminard sold 15,918 shares of the stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the transaction, the executive vice president owned 16,994 shares in the company, valued at approximately $4,367,458. This trade represents a 48.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 87,569 shares of company stock worth $23,064,544 over the last three months. Company insiders own 0.16% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Johnson Rice reaffirmed a "buy" rating on shares of Johnson & Johnson in a research report on Monday, August 3rd. UBS Group initiated coverage on shares of Johnson & Johnson in a research report on Wednesday, September 2nd. They issued a "buy" rating and a $320.00 price objective for the company. Weiss Ratings upgraded shares of Johnson & Johnson from a "buy (b-)" rating to a "buy (b)" rating in a research note on Friday, July 24th. TD Cowen upped their target price on shares of Johnson & Johnson from $250.00 to $300.00 and gave the company a "buy" rating in a report on Monday, July 13th. Finally, Royal Bank Of Canada raised their target price on shares of Johnson & Johnson from $265.00 to $287.00 and gave the company an "outperform" rating in a research note on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $274.13.

Johnson & Johnson Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.